HumeCare+ is built for someone who's already decided GLP-1 medication is worth considering but doesn't want to lose muscle along with fat, and doesn't want to guess whether their dose is doing what it's supposed to
The latter possibility is consistent with the report that KLF9 acts as a transcriptional mediator of glucocorticoid-regulated, KLF9 family member KLF2 in macrophages to promote inflammation (Chinenov et al., 2014)
Vision Our vision is to become the first contact for student entrepreneurs and a vital part of promoting student-led startups in the Twente region
Over the last few years, the use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists) for managing type 2 diabetes has dramatically increased
In early clinical trials, patients on GLP-1 agonists have achieved weight loss of 1520%, compared to the 510% typically seen with previous medications. Holistic approach to GLP-1 drugs Beyond weight loss, GLP-1 agonists have demonstrated the ability to reduce major cardiovascular events, combat fatty liver disease and alleviate obesity-related complications such as knee pain, sleep apnea, and acid reflux
Declaration of patient consent: The authors certify that they have obtained all appropriate patient consent forms
